183 related articles for article (PubMed ID: 29663172)
1. Individual changes in neurocognitive functioning and health-related quality of life in patients with brain oligometastases treated with stereotactic radiotherapy.
van der Meer PB; Habets EJJ; Wiggenraad RG; Verbeek-de Kanter A; Lycklama À Nijeholt GJ; Zwinkels H; Klein M; Dirven L; Taphoorn MJB
J Neurooncol; 2018 Sep; 139(2):359-368. PubMed ID: 29663172
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study.
Habets EJ; Dirven L; Wiggenraad RG; Verbeek-de Kanter A; Lycklama À Nijeholt GJ; Zwinkels H; Klein M; Taphoorn MJ
Neuro Oncol; 2016 Mar; 18(3):435-44. PubMed ID: 26385615
[TBL] [Abstract][Full Text] [Related]
3. Quality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial.
Kepka L; Tyc-Szczepaniak D; Osowiecka K; Sprawka A; Trąbska-Kluch B; Czeremszynska B
Clin Transl Oncol; 2018 Feb; 20(2):150-159. PubMed ID: 28616720
[TBL] [Abstract][Full Text] [Related]
4. Quality of life in patients with limited (1-3) brain metastases undergoing stereotactic or whole brain radiotherapy : A prospective study of the DEGRO QoL working group.
Steinmann D; Vordermark D; Gerstenberg W; Aschoff R; Gharbi N; Müller A; Schäfer C; Theodorou M; Wypior HJ; Geinitz H;
Strahlenther Onkol; 2020 Jan; 196(1):48-57. PubMed ID: 31418046
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition.
Geens W; Vanlaer N; Nijland L; Van Laere S; Schwarze JK; Bruneau M; Neyns B; Rogiers A; Duerinck J
J Neurooncol; 2024 May; 168(1):159-169. PubMed ID: 38502281
[TBL] [Abstract][Full Text] [Related]
6. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis.
Li J; Bentzen SM; Li J; Renschler M; Mehta MP
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):64-70. PubMed ID: 18406884
[TBL] [Abstract][Full Text] [Related]
7. Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL.
Caissie A; Nguyen J; Chen E; Zhang L; Sahgal A; Clemons M; Kerba M; Arnalot PF; Danjoux C; Tsao M; Barnes E; Holden L; Danielson B; Chow E
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1238-45. PubMed ID: 22172909
[TBL] [Abstract][Full Text] [Related]
8. The neurocognitive function change criteria after whole-brain radiation therapy for brain metastasis, in reference to health-related quality of life changes: a prospective observation study.
Nakano T; Aoyama H; Saito H; Tanabe S; Tanaka K; Maruyama K; Oshikane T; Ohta A; Abe E; Kaidu M
BMC Cancer; 2020 Jan; 20(1):66. PubMed ID: 31996182
[TBL] [Abstract][Full Text] [Related]
9. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
[TBL] [Abstract][Full Text] [Related]
10. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results.
Soffietti R; Kocher M; Abacioglu UM; Villa S; Fauchon F; Baumert BG; Fariselli L; Tzuk-Shina T; Kortmann RD; Carrie C; Ben Hassel M; Kouri M; Valeinis E; van den Berge D; Mueller RP; Tridello G; Collette L; Bottomley A
J Clin Oncol; 2013 Jan; 31(1):65-72. PubMed ID: 23213105
[TBL] [Abstract][Full Text] [Related]
11. Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials.
Caramanna I; Bottomley A; Drijver AJ; Twisk J; van den Bent M; Idbaih A; Wick W; Pe M; Klein M; Reijneveld JC;
Eur J Cancer; 2021 Feb; 144():162-168. PubMed ID: 33348088
[TBL] [Abstract][Full Text] [Related]
12. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function.
Li J; Bentzen SM; Renschler M; Mehta MP
J Clin Oncol; 2007 Apr; 25(10):1260-6. PubMed ID: 17401015
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life after stereotactic radiosurgery in patients with brain metastases.
Albers EAC; de Ligt KM; van de Poll-Franse LV; Compter A; de Ruiter MB; Schagen SB
Support Care Cancer; 2023 Nov; 31(12):720. PubMed ID: 38008876
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Minniti G; Scaringi C; Baldoni A; Lanzetta G; De Sanctis V; Esposito V; Enrici RM
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):285-91. PubMed ID: 23642624
[TBL] [Abstract][Full Text] [Related]
15. Whole brain radiotherapy versus stereotactic radiosurgery for 4-10 brain metastases: a phase III randomised multicentre trial.
Zindler JD; Bruynzeel AME; Eekers DBP; Hurkmans CW; Swinnen A; Lambin P
BMC Cancer; 2017 Jul; 17(1):500. PubMed ID: 28743240
[TBL] [Abstract][Full Text] [Related]
16. Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: A longitudinal study spanning two decades.
Boele FW; den Otter PWM; Reijneveld JC; de Witt Hamer PC; van Thuijl HF; Lorenz LMC; Wesseling P; Lagerwaard FJ; Taphoorn MJB; Kouwenhoven MCM; Snijders TJ; Douw L; Klein M
Neuro Oncol; 2023 Feb; 25(2):351-364. PubMed ID: 35908832
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of pre- and post-treatment health-related quality of life in predicting survival of patients with brain metastases.
Wong E; Rowbottom L; Tsao M; Zhang L; McDonald R; Danjoux C; Barnes E; Chan S; Chow E
CNS Oncol; 2017 Apr; 6(2):119-129. PubMed ID: 28425773
[TBL] [Abstract][Full Text] [Related]
18. Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033.
Dirven L; Reijneveld JC; Taphoorn MJB; Coens C; El-Badawy SA; Tzuk-Shina T; Bravo-Marques J; Back M; Stalpers LJA; Stupp R; Baumert BG; Seidel C
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):90-100. PubMed ID: 30716525
[TBL] [Abstract][Full Text] [Related]
19. Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma.
Noll KR; Bradshaw ME; Weinberg JS; Wefel JS
Psychooncology; 2017 May; 26(5):617-624. PubMed ID: 26677053
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
